ENTITY
Biogen Inc

Biogen Inc (BIIB US)

142
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products address diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis.
more
26 May 2018 07:11

The Week That Was In North Asia@Smartkarma: A Week of Cancellations & Baby Come Back

This past week was one of cancellations, highlighted by Trump cancelling his meeting with Kim Jong-Un and the Hyundai Motor Group cancelling the...

Logo
258 Views
Share
25 May 2018 10:35

FSC Chairman Speaks on Decision Framework

An article in the 24 May issue of BusinessKorea  (link below) reports on a talk given by Financial Services Commission (FSC) Chairman Choi...

Share
04 May 2018 22:02

Samsung BioLogics and Biogen: Who Had Control?

The controversy surrounding Samsung Biologics Co., Ltd (207940 KS) 's booking of a fair value gain in 2015 relates to their claim of a "loss of...

Share
12 Apr 2018 23:44

A Conversation with Biogen

Biogen Inc (BIIB US) is Samsung Biologics Co., Ltd (207940 KS) 's minority (5.4%) partner in the Samsung Bioepis JV that manufactures and sells...

Share
bearishBiogen Inc
15 Mar 2018 22:36

Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset

On 12 March 2018, Biogen Inc (BIIB US) announced an agreement to acquire Pfizer Inc (PFE US)'s first-in-class, Phase 2b ready AMPA receptor...

Logo
297 Views
Share
x